Key Ratio
USD
9.97
- (0.5%)
NASDAQ:BCRX, BIOCRYST PHARMACEUTICALS, INC.
Industry: Biotechnology
End of Day: 9 May 2025 GMT-4
Income Statement Ratios
Fiscal
Gross Profit Margin
98.60%
Net Profit Margin (Adj.)
-61.20%
Return on Equity (Adj.)
17.90%
Fiscal (USD)
Period End Date
Financials
Revenue
Gross Profit
EBITDA
Operating Profit
Net Income (To Shareholders)
Net Income (Adj.)
Ratios
Gross Profit Margin
EBITDA Margin
Operating Margin
Net Profit Margin (Adj.)
Return on Equity (Adj.)
Return on Equity (Adj.) 3Y
Return on Equity (Adj.) 5Y
Return on Assets (Adj.)
Return On Invested Capital (Adj.)
ROIIC 3Y
ROIIC 10Y
Degree Of Op. Leverage (EBIT)
Degree Of Op. Leverage (CFO)
Rule Of 40 (EBITDA)
Rule Of 40 (FCF)
Per Share
Revenue / Share
Operating Profit / Share
Diluted EPS
Diluted EPS (Adj.)
FY23
31 Dec 2023
LTM23 Q4
PR
31 Dec 2023
331
331
326
326
-117
-117
-103
-103
-226
-226
-141
-141
98.6%
98.6%
-35.6%
-35.6%
-35.6%
-35.6%
-61.2%
-61.2%
25.0%
17.9%
63.9%
63.4%
-211.0%
89.6%
-14.3%
-14.3%
-
-
38.0%
40.8%
-17.4%
-16.8%
-
-
-
-
-13.2
-13.2
-
-11.5
1.6
1.6
-0.5
-0.5
-1.2
-1.2
-1.2
-1.2
In Millions except per share items.
Balance Sheet Ratios
Fiscal
Current Ratio
5.50x
Cash Ratio
4.40x
Total Debt to Equity Ratio
-0.500x
Fiscal (USD)
Period End Date
Financials
Short Term Cash Investments
Total Assets
Total Debt
Total Liabilities
Total Equity
Ratios
Current Ratio
Cash Ratio
Total Debt to Equity Ratio
Net Debt (Cash) to Equity
Net Debt (Cash) to NTA
Cash Conversion Cycle
Avg Days Sales Out.
Avg Days Inventory Out.
Avg Days Payables Out.
Per Share
Total Assets / Share
Book Value/Share
Tangible Book Value / Share
Total Debt / Share
Cash / Share
Net Debt (Cash) / Share
FY23
31 Dec 2023
LTM23 Q4
PR
31 Dec 2023
388
388
516
516
741
845
972
972
-294
-410
-
5.5x
-
4.4x
-0.4x
-0.5x
-1.2x
-1.1x
-0.2x
-0.3x
-
1,293
59.0
59.0
-
1,872
-
634
2.5
2.5
-1.4
-2.0
-8.2
-8.2
3.6
4.1
1.9
1.9
1.7
2.2
In Millions except per share items.
Cash Flow Ratios
Fiscal (USD, MM)
Cash From Operations
-110
CAPEX
-
Free Cash Flow (FCF)
-112
Fiscal (USD)
Period End Date
Financials
CFO bef. W.C. Changes
Cash From Operations
CAPEX
Cash Flow From Investing
Cash Flow From Financing
Free Cash Flow (FCF)
Ratios
FCF Margin
Quality Of Earnings
Dividend Payout Ratio
Per Share
Cash From Operations / Share
Free Cash Flow / Share
Dividend / Share
Special Dividend / Share
FY23
31 Dec 2023
LTM23 Q4
PR
31 Dec 2023
-
-
-
-110
-
-
-
-
-
-
-
-112
-
-33.9%
-
-
-
-
-
-0.5
-
-0.5
-
-
-
-
In Millions except per share items.
Valuation Ratios
Fiscal
Price / Sales
3.70x
Price / Earnings (Adj.)
-8.10x
Price / Tangible Book
-0.70x
Fiscal (USD)
Period End Date
Dividend Yield
Special Dividend Yield
Price / Sales
Price / Earnings (Adj.)
Price / Book
Price / Tangible Book
Price / CFO
Price / FCF
EV / EBIT
FY23
31 Dec 2023
LTM23 Q4
PR
31 Dec 2023
-
-
-
-
3.7x
3.7x
-8.1x
-8.1x
-4.2x
-3.0x
-0.7x
-0.7x
-
-11.2x
-
-11.0x
-14.8x
-14.8x
Other Ratios
Fiscal (USD)
Period End Date
Revenue Growth
Year-On-Year
3 Year CAGR
5 Year CAGR
10 Year CAGR
Operating Profit Growth
Year-On-Year
3 Year CAGR
5 Year CAGR
10 Year CAGR
Net Income (Adj.) Growth
Year-On-Year
3 Year CAGR
5 Year CAGR
10 Year CAGR
Diluted (Adj.) EPS Growth
Year-On-Year
3 Year CAGR
5 Year CAGR
10 Year CAGR
Cash From Operations Growth
Year-On-Year
3 Year CAGR
5 Year CAGR
10 Year CAGR
Free Cash Flow Growth
Year-On-Year
3 Year CAGR
5 Year CAGR
10 Year CAGR
FY23
31 Dec 2023
LTM23 Q4
PR
31 Dec 2023
22.4%
22.4%
165.0%
165.0%
-
74.2%
-
34.3%
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Fiscal (USD)
Period End Date
Market Capitalization
Total Enterprise Value
Shares Outstanding
FY23
31 Dec 2023
LTM23 Q4
PR
31 Dec 2023
1.0906b
1.0906b
1.5384b
1.5384b
205.771m
205.771m
- Figures shown are in its reported currency unless stated otherwise.
- Net Income and its respective ratios are normalised for one-off items unless stated otherwise.
- PR = Press Release
- FYC = Financial Year Change
Make Smart Investment Choices
GoodWhale Pte. Ltd.
1557 Keppel Road, #01-01
Singapore 089066
Singapore 089066
